Autopsy report · NCT00865878
ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients
Cause of deathRegulatory or ethics
“Orphan Drug Designation for this indication not granted”
Life of this trial
- Registered 2 months before it started.
- Ran for about 2 years 4 months before it stopped.
- 6 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- DUSA Pharmaceuticals, Inc.
- Sponsor type
- Industry
- Conditions
- Actinic Keratoses; Skin Neoplasms
- Interventions
- Aminolevulinic Acid; Vehicle
- Participants
- 6
- Sites
- 7
- Countries
- United States
Trials that died the same way
- A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck
“After loss of orphan drug status in Korea, study was withdrawn due to Regulatory Authority request. Patients will be enrolled into NCT01075828 instead.” - Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - Endodontics
“Manufacturer discontinued drug before any participants could be enrolled.” - BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome
“Drug unavailable” - A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
“Company decided not to pursue the development of this drug in this patient population at this time” - TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
“Drug no longer available”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.